Which patients are considered high‑risk or very‑high‑risk and therefore require intensified lipid‑lowering therapy when adjusting statin therapy?

Risk Stratification for Intensifying Lipid-Lowering Therapy

Patients requiring intensified lipid-lowering therapy fall into two categories: high-risk patients (clinical ASCVD) and very-high-risk patients (clinical ASCVD with multiple major events or one major event plus multiple high-risk conditions), with very-high-risk patients warranting LDL-C targets below 70 mg/dL and consideration of non-statin therapies added to maximally tolerated statins. 1

Very High-Risk Patients

Very high-risk status is defined by patients with clinical ASCVD who have either: 1

• History of multiple major ASCVD events, OR 1
• One major ASCVD event PLUS multiple high-risk conditions 1

Major ASCVD Events Include:

• Recent acute coronary syndrome (within the past 12 months) 1
• History of myocardial infarction 1
• History of ischemic stroke 1
• Symptomatic peripheral arterial disease 1

High-Risk Conditions Include:

• Age ≥65 years 1
• Heterozygous familial hypercholesterolemia 1
• History of prior coronary artery bypass grafting or percutaneous coronary intervention outside of the major ASCVD events 1
• Diabetes mellitus 1
• Hypertension 1
• Chronic kidney disease (eGFR 15-59 mL/min/1.73 m²) 1
• Current smoking 1
• Persistently elevated LDL-C (≥100 mg/dL) despite maximally tolerated statin therapy and ezetimibe 1
• History of congestive heart failure 1

Treatment Approach for Very High-Risk:

• Use maximally tolerated statin therapy plus ezetimibe when LDL-C remains ≥70 mg/dL 1
• Consider adding PCSK9 inhibitor when LDL-C remains ≥70 mg/dL on maximally tolerated statin plus ezetimibe, though cost-effectiveness is low at current pricing 1
• Recent evidence supports upfront combination therapy (statin plus ezetimibe) in very high-risk patients to achieve LDL-C targets as early as possible 2

High-Risk Patients (Clinical ASCVD)

All patients with established clinical ASCVD are considered high-risk and require intensive lipid-lowering therapy: 1

Clinical ASCVD Includes:

• Acute coronary syndromes 1
• History of myocardial infarction 1
• Stable or unstable angina 1
• Coronary or other arterial revascularization 1
• Stroke 1
• Transient ischemic attack 1
• Peripheral arterial disease of atherosclerotic origin 1

Treatment Approach for High-Risk:

• Initiate or continue high-intensity statin therapy aiming for ≥50% LDL-C reduction in patients ≤75 years 1
• If high-intensity statin is contraindicated or causes side effects, use moderate-intensity statin targeting 30-49% LDL-C reduction 1
• For patients >75 years, moderate- or high-intensity statin is reasonable after evaluating potential benefits, adverse effects, drug interactions, frailty, and patient preferences 1

Additional High-Risk Primary Prevention Categories

Severe Primary Hypercholesterolemia:

• LDL-C ≥190 mg/dL (≥4.9 mmol/L) without calculating 10-year ASCVD risk 1
• Begin high-intensity statin therapy 1
• Add ezetimibe if LDL-C remains ≥100 mg/dL 1
• Consider PCSK9 inhibitor if LDL-C remains ≥100 mg/dL on statin plus ezetimibe with multiple ASCVD risk factors 1

Diabetes Mellitus (Ages 40-75):

• Patients with diabetes and LDL-C ≥70 mg/dL should start moderate-intensity statin without calculating 10-year risk 1
• Higher-risk diabetic patients (multiple risk factors or ages 50-75) should receive high-intensity statin to reduce LDL-C by ≥50% 1
• Most diabetic patients in this age range have intermediate or high 10-year ASCVD risk (≥7.5%) 1

Primary Prevention with Elevated 10-Year Risk:

• Adults 40-75 years without diabetes, LDL-C ≥70 mg/dL, and 10-year ASCVD risk ≥7.5% should start moderate-intensity statin after risk discussion 1
• Those with 10-year risk ≥20% may benefit from high-intensity statin for maximal risk reduction 1

Critical Implementation Points

Common pitfall: Real-world data shows only 37% of ASCVD patients achieve LDL-C <70 mg/dL, with only 34% receiving guideline-concordant high-intensity statin therapy 3. This represents a significant treatment gap requiring aggressive implementation of combination therapies earlier in the treatment course 2, 4.

Mortality benefit: Patients achieving LDL-C <55 mg/dL at follow-up demonstrate the lowest mortality rates (11.02% vs 18.26% overall) in post-myocardial infarction cohorts 4, supporting aggressive early treatment intensification in very high-risk patients.